go back

Revefenacin (Yupelri) Inhalation Solution

Hawaii rates for HCPCS J7677

Revefenacin inhalation solution, FDA-approved final product, noncompounded, administered through DME, 1 mcg

Rates data updated July 2026.

Facilitymedian $0 · 10th–90th $0$00%20%40%90th$0Professionalmedian $0 · 10th–90th $0$00%50%10th$0$0.0$0.1$0.1$0.2

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Professional
Modifier
Global
Typical Low
$0.20
Median
$0.20
Typical High
$0.20
Cigna
Setting
Professional
Modifier
Global
Typical Low
$0.20
Median
$0.20
Typical High
$0.24
HMSA
Setting
Professional
Modifier
Global
Typical Low
$0.28
Median
$0.28
Typical High
$0.28
Kaiser Permanente
Setting
Professional
Modifier
Global
Typical Low
$0.20
Median
$0.24
Typical High
$0.38
United
Setting
Facility
Modifier
Global
Typical Low
$0.02
Median
$0.02
Typical High
$0.10
United
Setting
Professional
Modifier
Global
Typical Low
$0.20
Median
$0.20
Typical High
$0.30